[
  {
    "id": 291,
    "question": "Rt small thalamic hemorrhage since one day, BP normal, pic attached no hydro or ventricular extension what to do next",
    "option_a": "(Prophylaxis LMWH): Correct because it reduces the risk of thromboembolic complications in a patient with a stable hemorrhage. \u2022 Option B (EVD): Incorrect, as external ventricular drainage is indicated in cases with hydrocephalus or significant intraventricular bleeding, which is not present in this patient.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThis question focuses on the management of a patient with a small intracerebral hemorrhage, specifically addressing the prevention of secondary thromboembolic complications. Once a hemorrhage is stable, prophylactic measures to minimize venous thromboembolism become paramount.\n\n**Pathophysiology**\n\nA small thalamic hemorrhage, when stable and not complicated by hydrocephalus or ventricular extension, still puts the patient at risk for venous thromboembolism due to prolonged immobilization. Low Molecular Weight Heparin (LMWH) acts by inhibiting factor Xa (and to a lesser extent, thrombin), thereby reducing the risk of clot formation without significantly increasing the chance of rebleeding when administered at the correct time.\n\n**Clinical Correlation**\n\nIn this case, the patient\u2019s blood pressure is normal and imaging confirms that the hemorrhage is confined to the thalamus with no evidence of mass effect or hydrocephalus. This scenario supports the initiation of prophylactic anticoagulation to prevent deep venous thrombosis (DVT) as part of secondary prevention.\n\n**Diagnostic Approach**\n\nNeuroimaging helps assess the size and nature of the hemorrhage. Differential diagnoses might include hemorrhagic transformation of an ischemic stroke or a ruptured aneurysm; however, these alternatives are less likely given the imaging findings and absence of hydrocephalus.\n\n**Management Principles**\n\nThe first step involves ensuring hemodynamic stability and controlling blood pressure. If the hemorrhage is confirmed to be stable (typically after the first 24 hours), prophylactic LMWH is recommended to lower the risk of DVT. In special populations such as pregnant women, LMWH is generally considered safe (category B) with minimal placental transfer, and in lactating mothers, LMWH remains the preferred anticoagulant given its low risk of transmission through breast milk.\n\n**Option Analysis**\n\n\u2022 Option A (Prophylaxis LMWH): Correct because it reduces the risk of thromboembolic complications in a patient with a stable hemorrhage. \u2022 Option B (EVD): Incorrect, as external ventricular drainage is indicated in cases with hydrocephalus or significant intraventricular bleeding, which is not present in this patient.\n\n**Clinical Pearls**\n\n1. In patients with intracerebral hemorrhage, the initiation of VTE prophylaxis should be timed appropriately (after 24 hours) to avoid rebleeding. 2. A stable, small hemorrhage without ventricular involvement allows for safe prophylactic anticoagulation.\n\n**Current Evidence**\n\nLatest guidelines from stroke and neurosurgical societies support early prophylactic anticoagulation in patients with stable intracerebral hemorrhage to prevent DVT. Recent studies continue to refine optimal timing and dosing strategies to maximize safety and efficacy while minimizing the risk of hematoma expansion.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "id": 292,
    "question": "Male with progressive myelopathy attached image clearly showing slow void, and long cord signal changes, dx",
    "option_a": "(DAVF): Correct, as the combination of progressive myelopathy and MRI findings with slow flow voids and elongated cord signal anomalies is classic for this diagnosis. Alternative options such as multiple sclerosis, transverse myelitis, or spinal tumors do not typically show the vascular flow voids on imaging.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThis question examines the identification of a spinal vascular malformation as the cause of progressive myelopathy. The key concept is understanding that chronic venous congestion due to abnormal arteriovenous shunting can lead to spinal cord dysfunction over time.\n\n**Pathophysiology**\n\nSpinal dural arteriovenous fistula (DAVF) is characterized by an abnormal connection between a radiculomeningeal artery and a medullary vein. This shunt elevates venous pressure, leading to cord congestion and ischemia. The chronic venous hypertension results in progressive myelopathy due to a combination of cord edema and insufficient perfusion.\n\n**Clinical Correlation**\n\nPatients with DAVF typically present with slowly progressive symptoms such as lower extremity weakness, sensory changes, and sphincter dysfunction. The MRI findings of long-segment T2 hyperintensity with serpiginous flow voids strongly suggest the presence of dilated, abnormal vessels consistent with DAVF, correlating directly with the progressive clinical picture.\n\n**Diagnostic Approach**\n\nThe diagnostic strategy includes MRI which reveals both the cord signal changes and the characteristic flow voids of dilated vessels. Differential diagnoses include multiple sclerosis (often multifocal and ovoid lesions without abnormal flow voids), transverse myelitis (acute inflammatory process without dilated vessels), and spinal neoplasms (typically focal with mass effect rather than diffuse vascular changes).\n\n**Management Principles**\n\nThe first-line treatment for spinal DAVF is endovascular embolization, aiming to interrupt the abnormal shunt. When embolization is not feasible or is incomplete, surgical disconnection of the fistula is considered. In pregnant patients, management requires a multidisciplinary approach given the risks associated with radiation exposure and anesthesia; tailored intervention with minimized fluoroscopy time is advised. For lactating patients, similar considerations apply with close monitoring and counseling regarding procedural risks.\n\n**Option Analysis**\n\n\u2022 Option A (DAVF): Correct, as the combination of progressive myelopathy and MRI findings with slow flow voids and elongated cord signal anomalies is classic for this diagnosis. Alternative options such as multiple sclerosis, transverse myelitis, or spinal tumors do not typically show the vascular flow voids on imaging.\n\n**Clinical Pearls**\n\n1. When evaluating progressive myelopathy, always inspect MRI images for abnormal flow voids which may indicate a DAVF. 2. Early recognition of spinal DAVF is critical to prevent irreversible spinal cord damage.\n\n**Current Evidence**\n\nRecent research and clinical guidelines emphasize the importance of prompt diagnosis and intervention in spinal DAVF. Newer endovascular techniques and surgical approaches have demonstrated improved outcomes, and current studies focus on optimizing the timing and method of intervention to maximize neurological recovery.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "id": 293,
    "question": "Male with renal impairment, stroke, angiokeratoma pic asking about enzyme supp",
    "option_a": "(alpha",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nFabry disease is an X\u2010linked lysosomal storage disorder caused by a deficiency in the enzyme alpha-galactosidase A. This deficiency leads to the accumulation of glycosphingolipids, particularly globotriaosylceramide (Gb3), in various cell types and tissues, including vascular endothelial cells, kidney, heart, and skin.\n\n**Pathophysiology**\n\nThe lack of functional alpha-galactosidase A results in progressive storage of Gb3 within lysosomes. This accumulation induces cellular damage, microvascular dysfunction, and inflammatory changes that contribute to end-organ damage such as renal impairment, cerebrovascular ischemia (stroke), and characteristic skin findings (angiokeratomas). In men especially, the classic phenotype can be severe, with early manifestations affecting multiple systems.\n\n**Clinical Correlation**\n\nPatients often present with a combination of symptoms including neuropathic pain, angiokeratomas (small, reddish-purple skin lesions), renal impairment, and an increased risk for cerebrovascular events. The concurrence of renal dysfunction, stroke, and skin lesions in a male patient is highly suggestive of Fabry disease.\n\n**Diagnostic Approach**\n\nDiagnosis is confirmed by measuring alpha-galactosidase A activity in plasma or leukocytes and can be supported by genetic testing for mutations in the GLA gene. Differential diagnoses include other lysosomal storage disorders such as Gaucher disease (beta\u2010glucocerebrosidase deficiency) and Pompe disease (alpha\u2010glucosidase deficiency), which have distinct clinical and enzymatic profiles.\n\n**Management Principles**\n\nThe first-line treatment is enzyme replacement therapy (ERT) with recombinant alpha-galactosidase A, which helps reduce substrate accumulation and slow disease progression. Adjunctive management includes supportive interventions for renal, cardiac, and cerebrovascular complications. In pregnancy and lactation, treatment decisions must carefully balance maternal benefits against potential fetal risks, and multidisciplinary consultation is advised as current data on ERT during pregnancy remain limited.\n\n**Option Analysis**\n\nOption A (alpha-galactosidase, here noted as 'Galtcosidase') is correct since it directly addresses the enzyme deficiency in Fabry disease. Other enzymes listed, such as beta-glucocerebrosidase (associated with Gaucher disease), alpha-glucosidase (associated with Pompe disease), or galactocerebrosidase (associated with Krabbe disease), are unrelated to the pathogenesis of Fabry disease.\n\n**Clinical Pearls**\n\n1. The triad of renal impairment, stroke, and angiokeratomas in a male patient should prompt consideration of Fabry disease. 2. Early initiation of ERT may attenuate long-term organ damage. 3. Enzyme activity assays coupled with genetic testing are crucial for a definitive diagnosis.\n\n**Current Evidence**\n\nRecent clinical studies underscore the benefits of early intervention with ERT in Fabry disease to delay progression of organ dysfunction. Current guidelines advocate for a multidisciplinary approach, with close attention to cardiac and renal monitoring, and emerging research continues to refine optimal dosing and treatment initiation timings.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "id": 294,
    "question": "Scenario patient feeling unwell, then start seeing animals after which he had decreased LOC intubated, decerebrate posturing CT brain attached showed hyperdense basilar sign otherwise no clear ischemic changes what to do next",
    "option_a": "(CTA) is correct because CTA provides non",
    "option_b": "(EEG) is incorrect as it evaluates brain electrical activity and is not useful in diagnosing vascular occlusions.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nBasilar artery occlusion is a serious form of ischemic stroke affecting the posterior circulation. The hyperdense basilar artery sign on non-contrast CT is a key radiological finding that raises suspicion for this condition.\n\n**Pathophysiology**\n\nAn occlusive thrombus or embolus within the basilar artery can lead to reduced blood flow to critical brainstem regions. The hyperdense appearance on CT reflects the clot\u2019s density relative to normal blood, while the resultant ischemia causes brainstem dysfunction, which may manifest as altered consciousness or abnormal posturing.\n\n**Clinical Correlation**\n\nIn the described scenario, the patient\u2019s initial nonspecific symptoms rapidly progress to severe neurological compromise (decreased level of consciousness, decerebrate posturing) indicating brainstem involvement. The hyperdense basilar sign on CT strongly suggests a vascular occlusion requiring urgent further imaging and intervention.\n\n**Diagnostic Approach**\n\nFollowing a non-contrast CT that reveals a hyperdense basilar artery, the next step is to perform CT angiography (CTA) to confirm the location and extent of the occlusion, assess collateral circulation, and guide reperfusion strategies. The differential includes non-ischemic causes of brainstem dysfunction (e.g., encephalopathy, metabolic disturbances) but these do not explain the hyperdense vascular sign.\n\n**Management Principles**\n\nManagement involves rapid reperfusion, which may include intravenous thrombolysis (if within the therapeutic window, usually 4.5 hours) and endovascular thrombectomy. Intensive care monitoring and supportive measures are essential. In pregnant patients, risk-benefit analysis regarding thrombolysis or endovascular interventions should be performed in conjunction with obstetrical consultation, as the safety profiles of these treatments during pregnancy require careful consideration.\n\n**Option Analysis**\n\nOption A (CTA) is correct because CTA provides non-invasive, rapid confirmation of vascular occlusion by visualizing the basilar artery. Option B (EEG) is incorrect as it evaluates brain electrical activity and is not useful in diagnosing vascular occlusions.\n\n**Clinical Pearls**\n\n1. A hyperdense basilar artery sign on CT should prompt immediate vascular imaging with CTA. 2. Time is brain: rapid identification and treatment of basilar artery occlusion are crucial to prevent devastating brainstem infarction. 3. Endovascular therapy has become a key component in the management of large vessel occlusions.\n\n**Current Evidence**\n\nRecent guidelines and studies have reinforced the role of CTA in the acute stroke workup, with growing evidence supporting endovascular thrombectomy even in extended time windows for select patients. Current protocols emphasize rapid diagnosis and the integration of advanced neuroimaging to optimize outcomes.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "id": 295,
    "question": "What is the mechanism?",
    "option_a": "tramatic haemorrage",
    "option_b": "ICh",
    "option_c": "lobar haemorrage",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nIntracerebral hemorrhage (ICH) refers to bleeding within the brain tissue and is most commonly a spontaneous event due to hypertension, although other causes exist. Differentiating among traumatic hemorrhage, deep (hypertensive) ICH, and lobar hemorrhages is key in understanding the underlying pathology.\n\n**Pathophysiology**\n\nHypertensive ICH typically results from chronic hypertension causing degeneration of the small penetrating arteries (with Charcot-Bouchard microaneurysm formation), leading to rupture and bleeding into the brain parenchyma. In contrast, lobar hemorrhages often occur in the cerebral lobes and may be associated with cerebral amyloid angiopathy, particularly in the elderly, while traumatic hemorrhages result from injury.\n\n**Clinical Correlation**\n\nClinical presentations of ICH vary but generally include a sudden onset of neurological deficits, headache, and altered consciousness. The location of the hemorrhage (deep versus lobar) can provide clues about the underlying etiology: deep ICH is commonly linked to hypertension, whereas lobar hemorrhages suggest alternative causes.\n\n**Diagnostic Approach**\n\nNon-contrast CT is the first-line diagnostic tool to identify the location and extent of bleeding. History (including the presence or absence of trauma) and risk factors such as long-standing hypertension or amyloid angiopathy help differentiate the type of hemorrhage. Magnetic resonance imaging (MRI) may further characterize the hemorrhage and identify underlying lesions.\n\n**Management Principles**\n\nManagement of ICH includes aggressive blood pressure control, reversal of any coagulopathy, and supportive care in an intensive care setting. In cases of large hematomas or significant mass effect, surgical intervention may be considered. For pregnant or lactating patients, blood pressure targets remain similar; however, interventions must carefully weigh maternal neurological status against fetal risks, often necessitating multidisciplinary management.\n\n**Option Analysis**\n\nOption A (traumatic hemorrhage) is incorrect in a scenario without evidence of trauma. Option B (ICH) is correct because it aligns with the pathophysiology of spontaneous intracerebral hemorrhage typically seen in hypertensive patients. Option C (lobar hemorrhage) refers to a subtype generally associated with cerebral amyloid angiopathy and does not represent the general mechanism established for hypertensive ICH.\n\n**Clinical Pearls**\n\n1. Hypertensive ICH most often involves deep brain structures such as the basal ganglia and thalamus. 2. Distinguishing between spontaneous and traumatic hemorrhage is critical and relies heavily on patient history and imaging findings. 3. Rapid blood pressure management is a cornerstone of ICH treatment to prevent hematoma expansion.\n\n**Current Evidence**\n\nRecent clinical trials have supported intensive blood pressure control as a means to limit hematoma growth and improve outcomes in ICH. Research continues into minimally invasive surgical approaches, and updated guidelines emphasize individualized care that considers both the size and location of the hemorrhage.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "id": 296,
    "question": "What is the mechanism?",
    "option_a": "(Aneurysm rupture) is incorrect because the hemorrhage pattern in premesencephalic hemorrhage does not support an aneurysmal source. Option B (Atherosclerosis) is incorrect as it is associated with ischemic strokes rather than subarachnoid hemorrhage. Option C (Premesencephalic hemorrhage) is correct because it accurately describes the mechanism for this subtype of SAH. The previously marked answer (D) does not correspond to any of the relevant options provided.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nSubarachnoid hemorrhage (SAH) can occur due to a variety of mechanisms. Premesencephalic (or perimesencephalic) hemorrhage is a subtype of non-aneurysmal SAH characterized by bleeding in the cisternal spaces around the midbrain with a relatively benign clinical course.\n\n**Pathophysiology**\n\nUnlike aneurysmal SAH, which is typically due to aneurysm rupture and is associated with a high risk of rebleeding and vasospasm, premesencephalic hemorrhage is believed to result from venous or small arterial bleeding in the premesencephalic cisterns. It usually does not involve an aneurysm, and patients often experience a smoother recovery with fewer complications.\n\n**Clinical Correlation**\n\nPatients with premesencephalic hemorrhage tend to present with a sudden-onset headache that may be less severe than that associated with aneurysmal SAH. Neurological deficits are often minimal, and the clinical course is more benign. The limited blood spread on imaging distinguishes it from aneurysmal SAH.\n\n**Diagnostic Approach**\n\nInitial evaluation with non-contrast CT typically shows blood localized around the midbrain without the extensive subarachnoid spread seen in aneurysm rupture. Vascular imaging (CTA, MRA, or digital subtraction angiography) is undertaken to rule out aneurysms. Differential diagnoses include aneurysmal SAH and other non-aneurysmal causes of SAH, which are differentiated based on the distribution of blood on imaging and clinical severity.\n\n**Management Principles**\n\nManagement is generally conservative, including bed rest, analgesia, and close neurological monitoring. Nimodipine is less frequently used because the risk of vasospasm is much lower compared to aneurysmal SAH. In pregnant or lactating women, conservative management is especially preferred unless there is evidence of complications, with decisions being made in consultation with neurology and maternal-fetal medicine specialists.\n\n**Option Analysis**\n\nOption A (Aneurysm rupture) is incorrect because the hemorrhage pattern in premesencephalic hemorrhage does not support an aneurysmal source. Option B (Atherosclerosis) is incorrect as it is associated with ischemic strokes rather than subarachnoid hemorrhage. Option C (Premesencephalic hemorrhage) is correct because it accurately describes the mechanism for this subtype of SAH. The previously marked answer (D) does not correspond to any of the relevant options provided.\n\n**Clinical Pearls**\n\n1. Premesencephalic hemorrhage has a benign course compared to aneurysmal SAH, with lower rates of vasospasm and rebleeding. 2. The localization of bleeding on CT is a critical clue in differentiating premesencephalic hemorrhage from aneurysmal SAH. 3. Vascular imaging must be performed to exclude the presence of an aneurysm, even when a premesencephalic pattern is suspected.\n\n**Current Evidence**\n\nRecent studies have confirmed that patients with premesencephalic hemorrhage generally have excellent outcomes and benefit from conservative management. Updated guidelines recommend distinguishing this entity from aneurysmal SAH to ensure appropriate, less invasive management strategies are applied.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "id": 297,
    "question": "sickler pt come with stroke work up done and found to have multiple stenosis in AcA and McA. Ehat is the method of prevention?",
    "option_a": "aspirin",
    "option_b": "plavix",
    "option_c": "chronic transfusion",
    "option_d": "dual antiplate",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nSickle cell disease (SCD) predisposes patients to cerebrovascular complications because of the abnormal hemoglobin (HbS) that can polymerize under low oxygen conditions. This leads to recurrent vaso\u2010occlusion and chronic vascular injury. In the context of stroke prevention, reducing the proportion of sickled cells is paramount.\n\n**Pathophysiology**\n\nIn SCD, red blood cells containing HbS undergo polymerization during deoxygenation, leading to deformation and aggregation. The recurring infarctions and subsequent vessel wall injury result in stenosis in critical cerebral arteries such as the anterior cerebral (AcA) and middle cerebral (McA) arteries. Chronic transfusion therapy works by diluting the concentration of HbS, thus lowering the risk of further vaso\u2010occlusive events and progression of vasculopathy.\n\n**Clinical Correlation**\n\nPatients with SCD frequently develop cerebrovascular disease, which may manifest as stroke or transient ischemic attacks, particularly when arterial stenosis is present. A history of abnormal transcranial Doppler studies or a prior stroke indicates the need for aggressive measures to prevent recurrence.\n\n**Diagnostic Approach**\n\nThe workup includes transcranial Doppler ultrasound (especially in the pediatric population) to screen for increased velocities, brain MRI to delineate infarcted areas, and vascular imaging (CTA/MRA) to assess the degree and location of arterial stenoses. Differential diagnoses include other causes of stroke such as cardioembolic events or conventional atherosclerosis, but the presence of SCD directs the etiology to vaso\u2010occlusion mechanisms.\n\n**Management Principles**\n\nFirst\u2010line prevention for recurrent strokes in SCD is chronic transfusion therapy aimed at maintaining the percentage of HbS below a target threshold (often <30%). In addition, hydroxyurea is sometimes used in select patients to reduce vaso\u2010occlusive crises. For pregnant or lactating patients with SCD, transfusion protocols are modified with close monitoring to avoid iron overload and alloimmunization, while hydroxyurea is generally avoided during pregnancy.\n\n**Option Analysis**\n\n\u2022 Option A (aspirin): Although antiplatelet agents are standard in general stroke prevention, they do not address the underlying sickling process in SCD. \n\u2022 Option B (plavix): Similarly, clopidogrel is not indicated as a primary preventive measure in SCD-related strokes. \n\u2022 Option C (chronic transfusion): This is the evidence-based approach for secondary prevention in SCD patients with stroke, addressing the fundamental abnormality by reducing HbS levels. \n\u2022 Option D (dual antiplatelet): Dual antiplatelet therapy is used in atherosclerotic disease but is not the standard measure for stroke prevention in SCD.\n\n**Clinical Pearls**\n\n\u2022 Chronic transfusion therapy has been shown to reduce recurrent stroke risk in patients with SCD by decreasing the proportion of HbS. \n\u2022 Regular transcranial Doppler screening is a key preventive strategy in pediatric SCD populations.\n\n**Current Evidence**\n\nRecent trials and guidelines (for example, those emerging from the STOP and TWiTCH studies) have reinforced the use of chronic transfusion therapy as the cornerstone for preventing recurrent stroke events in patients with SCD.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "id": 298,
    "question": "What you will do:",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nLarge vessel atherosclerotic disease that leads to stroke is initially managed with optimized medical therapy rather than immediate intervention. The focus is on reducing the risk factors that contribute to plaque formation and thrombosis.\n\n**Pathophysiology**\n\nAtherosclerotic plaques develop in the carotid or other large cerebral vessels, which can lead to significant stenosis and increased risk of thromboembolic events. The systemic inflammatory process and endothelial dysfunction promote plaque instability. Medical therapy aims to stabilize plaques, control dyslipidemia, and reduce platelet aggregation.\n\n**Clinical Correlation**\n\nIn patients with symptomatic or high-grade carotid stenosis, the choice between medical management, endarterectomy, or stenting depends on the degree of stenosis, symptom status, and individual patient risk factors. Often, patients present with minor strokes or transient ischemic attacks and require risk factor modification as a first-line approach.\n\n**Diagnostic Approach**\n\nDiagnosis is supported by duplex ultrasound, CTA, or MRA to quantify the degree of stenosis. Differential diagnoses include cardioembolism and small vessel disease, which are managed differently.\n\n**Management Principles**\n\n\u2022 First-line management is optimized medical therapy, including antiplatelet agents (like aspirin), high-intensity statin therapy, and strict control of blood pressure and diabetes. \n\u2022 Carotid endarterectomy is reserved for symptomatic patients with high-grade stenosis (commonly >70%). \n\u2022 Carotid stenting is considered in patients who are not candidates for surgery. \nPregnancy and lactation: In pregnant patients, medication choices must consider fetal safety; low-dose aspirin may be continued, but statins are contraindicated. A tailored therapeutic plan is necessary.\n\n**Option Analysis**\n\n\u2022 Option 1 (Angioplasty alone): Not adequate as a sole therapy because angioplasty without stenting can lead to vessel recoil and restenosis. \n\u2022 Option 2 (Stent): Carotid stenting has a higher periprocedural stroke risk and is generally reserved for patients with contraindications to surgery. \n\u2022 Option 3 (Endarterectomy): While effective, it is not universally applied and is appropriate mainly in selected high-grade stenosed, symptomatic patients. \n\u2022 Option 4 (Medical therapy): This is the appropriate first-line intervention, focusing on aggressive risk factor modification and pharmacologic therapy.\n\n**Clinical Pearls**\n\n\u2022 Optimized medical therapy remains the cornerstone for initial management of most patients with large vessel cerebrovascular stenosis. \n\u2022 Revascularization techniques are specifically reserved for cases where the benefit outweighs the risks based on the degree of stenosis and symptomatology.\n\n**Current Evidence**\n\nRecent studies, including the CREST trial and evolving AHA/ASA guidelines, underscore the importance of initiating intensive medical therapy as the primary approach for stroke prevention in patients with carotid stenosis, with revascularization considered only in select high-risk patient populations.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "id": 299,
    "question": "Stroke all stroke workups mentioned except CTA asked what to do next",
    "option_a": "(CTA): Correct because it provides rapid, comprehensive vascular imaging necessary for acute stroke management. \n\u2022 Option B: Does not offer the comprehensive vascular assessment needed for immediate management decisions. Other non",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nIn the workup of acute stroke, after initial non-contrast imaging to rule out hemorrhage, rapid vascular imaging is critical to identify occlusions or stenoses that can guide acute therapeutic interventions.\n\n**Pathophysiology**\n\nCerebrovascular occlusions, particularly in large vessel strokes, require quick identification to determine candidacy for reperfusion therapies. Computed tomography angiography (CTA) provides detailed images of the cerebral vasculature, allowing for identification of vessel occlusions and stenosis patterns.\n\n**Clinical Correlation**\n\nIn an acute stroke setting, time is brain \u2013 rapid identification of a large vessel occlusion can lead to timely decisions regarding thrombolysis or thrombectomy, which are essential for improving outcomes.\n\n**Diagnostic Approach**\n\nThe usual diagnostic workflow in suspected acute ischemic stroke includes an initial non-contrast CT (NCCT) to exclude hemorrhage, followed by CTA to evaluate the arterial system. Differential diagnoses might include plain CT (which cannot assess vessel patency adequately), MRI/MRA (which is accurate but may not be as rapidly accessible), or carotid Doppler (limited to extracranial evaluation).\n\n**Management Principles**\n\nCurrent guidelines (such as those from the AHA/ASA) recommend that after an NCCT, CTA should be performed immediately to assess for large vessel occlusion, facilitating decision making regarding thrombolytic therapy or endovascular intervention. In pregnancy, non-contrast imaging is preferred initially to reduce radiation, but if CTA is necessary, precautions (such as abdominal shielding) should be taken. In lactating patients, CTA can be performed as the risk is minimal.\n\n**Option Analysis**\n\n\u2022 Option A (CTA): Correct because it provides rapid, comprehensive vascular imaging necessary for acute stroke management. \n\u2022 Option B: Does not offer the comprehensive vascular assessment needed for immediate management decisions. Other non-contrast studies or limited vascular studies are insufficient when CTA data is critical for reperfusion decision-making.\n\n**Clinical Pearls**\n\n\u2022 CTA is the modality of choice to rapidly evaluate the cerebral vasculature after initial stroke imaging. \n\u2022 Quick delineation of vascular status is essential for determining eligibility for advanced reperfusion therapies.\n\n**Current Evidence**\n\nRecent evidence and updated AHA/ASA guidelines continue to support the role of CTA as a critical next step in the imaging algorithm for acute ischemic stroke, affirming its place in current stroke protocols.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "id": 300,
    "question": "Patient with ESRD Scenario with pic showing rt superficial borderzone infarction at MCA/ACA territory asking about next investigation",
    "option_a": "(Brain CT angiography alone): Although it provides good intracranial detail, it is incomplete without neck imaging to evaluate the carotid arteries. \n\u2022 Option B (Conventional angiography): While being the gold standard, it is invasive and carries higher risks, especially in ESRD patients. \n\u2022 Option C: Implied to represent a comprehensive CTA (including both brain and neck vessels), which is the most appropriate next investigation given its noninvasive nature and ability to assess the entire cerebrovascular system.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nWatershed (borderzone) infarctions typically occur in areas between major cerebral arterial territories and are often due to hemodynamic compromise rather than embolic occlusion. In patients with conditions such as ESRD, who have a higher burden of atherosclerosis, the evaluation of both intracranial and extracranial vessels is crucial.\n\n**Pathophysiology**\n\nBorderzone infarcts result from hypoperfusion, where the distal territories of the cerebral arteries (such as the MCA and ACA territories) are inadequately supplied. This commonly occurs in the presence of significant arterial stenosis, especially at the carotid bifurcation, leading to a reduced perfusion pressure in these watershed regions.\n\n**Clinical Correlation**\n\nIn patients with ESRD, the risk of atherosclerotic disease is heightened. A superficial borderzone infarct as seen on imaging should prompt consideration of a hemodynamic mechanism, and a comprehensive vascular evaluation is necessary to determine the extent and location of any stenotic lesions.\n\n**Diagnostic Approach**\n\nThe optimal evaluation includes a CT angiography (CTA) that encompasses both the intracranial vessels and the cervical (extracranial) carotid arteries. Differential diagnoses include relying solely on brain CTA (which may miss extracranial pathology) or invasive conventional angiography, which carries unnecessary risk as a first-line investigation.\n\n**Management Principles**\n\nFor patients with suspected hemodynamic compromise from carotid stenosis, a comprehensive, noninvasive vascular imaging study (CTA of both brain and neck) is the first investigation of choice. In patients with ESRD, while the use of contrast is a consideration, the patient\u2019s renal status (often already on dialysis) modifies the risk-benefit ratio. In pregnant or lactating patients, contrast studies are approached cautiously with appropriate shielding and timing, though ESRD typically precludes pregnancy.\n\n**Option Analysis**\n\n\u2022 Option A (Brain CT angiography alone): Although it provides good intracranial detail, it is incomplete without neck imaging to evaluate the carotid arteries. \n\u2022 Option B (Conventional angiography): While being the gold standard, it is invasive and carries higher risks, especially in ESRD patients. \n\u2022 Option C: Implied to represent a comprehensive CTA (including both brain and neck vessels), which is the most appropriate next investigation given its noninvasive nature and ability to assess the entire cerebrovascular system.\n\n**Clinical Pearls**\n\n\u2022 In borderzone infarctions, always ensure that the vascular imaging covers both intracranial and extracranial territories. \n\u2022 ESRD patients are at increased risk for significant atherosclerotic disease and warrant comprehensive evaluation despite concerns regarding contrast media.\n\n**Current Evidence**\n\nThe latest stroke imaging protocols and guidelines emphasize the value of a comprehensive CTA that includes neck imaging to assess for extracranial carotid disease, particularly in cases of watershed infarcts. This approach minimizes risk while providing detailed vascular mapping to guide further management.",
    "exam_year": "2022",
    "exam_type": "Part II"
  }
]